Wegovy Tablets: What to Know, What Changes, and What Stays the Same

Wegovy tablets are an oral formulation of semaglutide approved for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease. While the active drug is the same as injectable Wegovy, the delivery, dosing discipline, absorption profile, and real-world experience differ in meaningful ways.

This guide explains:

  • what Wegovy tablets are approved to do
  • what actually changes compared to injections
  • what stays the same biologically and clinically
  • how to interpret the clinical trial data Novo Nordisk submitted
  • and what patients and clinicians should realistically expect

The FDA-Approved Indications (What’s Officially Preserved)

According to the label, Wegovy tablets are indicated in combination with a reduced-calorie diet and increased physical activity:

  • To reduce the risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with established cardiovascular disease and obesity or overweight
  • To reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight plus at least one weight-related comorbidity

Importantly:

  • The weight management indication is preserved
  • The cardiovascular risk-reduction indication is preserved
  • MASH / NASH is not an indication for Wegovy tablets at this time

That omission is likely related to oral bioavailability and hepatic exposure, not a lack of mechanistic plausibility. This mirrors the long-standing positioning of oral semaglutide (Rybelsus) versus injectable formulations.

What Wegovy Tablets Are (And Are Not)

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist that:

  • reduces appetite
  • increases satiety
  • slows gastric emptying
  • improves cardiometabolic risk factors over time

What’s different is how the drug enters the body.

Injectable Wegovy uses a subcutaneous depot with steady systemic exposure. Wegovy tablets rely on gastrointestinal absorption, which is inherently:

  • less efficient
  • more variable
  • more sensitive to timing and administration technique

This does not make the tablet inferior — but it does make discipline and expectations more important.

What Changes With Wegovy Tablets

1. Dosing and Administration Discipline

Wegovy tablets are taken once daily, not weekly.

Key requirements:

  • taken on an empty stomach
  • swallowed with plain water only
  • no food, drink, or other medications for a defined window afterward

Missed doses or improper timing matter more with oral GLP-1s than injectables. In practice, this is one of the most common reasons patients report “less effect.”

2. Absorption and Variability

Oral semaglutide has lower bioavailability than injected semaglutide. That’s expected.

What matters is not peak levels, but consistent exposure over time. Patients who follow dosing instructions closely tend to see outcomes that mirror injectable trajectories, while inconsistent administration leads to uneven results.

3. Side-Effect Timing

The types of side effects are familiar:

  • nausea
  • GI discomfort
  • early satiety

What changes is timing. With tablets, GI effects may cluster around dosing windows rather than weekly peaks. This can be mitigated with slower titration and adherence coaching.

What Stays the Same

Despite the different formulation, several things remain unchanged:

  • Mechanism of action (GLP-1 receptor agonism)
  • Appetite suppression and satiety signaling
  • Need for lifestyle integration
  • Chronic-use framing (this is not a short-term drug)
  • Expected trajectory: gradual, sustained weight loss over months — not weeks

The tablet does not “downgrade” Wegovy.
But it does change the margin for error.

What the Clinical Trial Data Actually Show (Novo’s Figure 7, Explained Simply)

Novo’s Figure 7 from the prescribing information packet in the clinical studies section evaluated Wegovy tablets in adults with obesity or overweight plus comorbidities over 64 weeks.

Weight Loss Outcomes

  • Average weight reduction with Wegovy tablets: ~13.6%
  • Placebo: ~2.4%
  • Difference vs placebo: ~11.2 percentage points

Responder outcomes:

  • ~76% lost ≥5% of body weight
  • ~60% lost ≥10%
  • ~47% lost ≥15%
  • ~28% lost ≥20%

Waist Circumference

  • Mean reduction: ~12 cm
  • Clinically meaningful central adiposity reduction

Blood Pressure

  • Systolic BP reduction: ~7 mmHg
  • Diastolic BP reduction: ~3 mmHg

These changes matter in aggregate cardiovascular risk, especially in patients with established CVD.

Lipids and Glycemic Markers

  • Modest reductions in total cholesterol and triglycerides
  • HbA1c reduction even in non-diabetic populations

These effects are secondary, but directionally consistent with injectable semaglutide data.

Who Wegovy Tablets May Be a Good Fit For

Potentially good candidates:

  • Patients averse to injections
  • Patients with stable daily routines
  • Those who previously tolerated GLP-1 therapy well
  • Patients prioritizing cardiovascular risk reduction alongside weight loss

Potentially poor candidates:

  • Highly variable schedules, or forgetfulness
  • Difficulty with fasting administration
  • Significant GI sensitivity
  • History of early GLP-1 discontinuation due to adherence challenges
  • Non-response to injectable GLP1s

Coverage and Access Considerations

Despite being a tablet, Wegovy is still:

  • a brand GLP-1
  • likely subject to prior authorization
  • often positioned under pharmacy benefit rules similar to injectables

Early rollout periods commonly involve:

  • PA delays
  • inconsistent formulary placement
  • step therapy confusion

Novo Nordisk is offering a discounted access program on their Wegovy Tablet web page, as low as $149/month for starter doses, and capped at $299/month for the max, maintenance doses. Coverage behavior tends to lag label science, not reflect it, so we’ll see how payers position.

Key Takeaways

  • Same drug, different mechanism
  • Tablets reduce needle burden, not complexity
  • Clinical weight loss outcomes are substantial when taken correctly
  • Cardiovascular risk-reduction claims are preserved
  • Coverage may be uneven early on
  • Expectations and adherence matter more than formulation

Where This Fits in the GLP-1 Landscape

If you’re comparing options or considering a switch, these may help:

Final framing

Wegovy tablets do not replace injectable GLP-1s.
They expand the menu — and in doing so, shift responsibility toward adherence and expectation management.

About Andrew

Hey! I’m Andrew Gilberto Vargas, a pharmacist and writer. I reflect on concepts that shape pharmacy benefits, drug access, leadership and meaning-making. Always curious, always learning.

Andrew Vargas, PharmD

About the Author

Andrew Vargas, PharmD is a Clinical Coding Pharmacist and founder of Pharmacist Write, where he translates managed-care and GLP-1 policy into practical insights for patients and professionals.

🧠 Read full bio · View all articles